Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) granted inducement stock options to two new employees under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted a total of 55,500 options on an effective date of May 4, 2026 at an exercise price of $7.02 per share. Options have a 10-year term and vest over four years: 25% on the first anniversary, then 6.25% each quarter for the following 12 quarters, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – FULC

-0.14%

1 alert

-0.14% News Effect

-$643K Valuation Impact

$458.44M Market Cap

1.08K Volume

On the day this news was published, FULC declined 0.14%, reflecting a mild negative market reaction. This price movement removed approximately $643K from the company's valuation, bringing the market cap to $458.44M at that time.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement details inducement stock option grants totaling 55,500 shares at an exercise price...

Analysis

This announcement details inducement stock option grants totaling 55,500 shares at an exercise price of $7.02, vesting over a four‑year schedule under Nasdaq Listing Rule 5635(c)(4). The grants are part of Fulcrum’s 2022 Inducement Stock Incentive Plan and reflect standard biotech hiring practices. In context of a stock trading below its $8.83 200‑day average and well under its $15.74 52‑week high, investors may watch ongoing clinical milestones and cash usage more closely than these routine equity awards.

Key Figures

Inducement options granted: 55,500 options Exercise price: $7.02 per share Number of employees: 2 employees +4 more

7 metrics

Inducement options granted 55,500 options Non-statutory stock options to two new employees under 2022 plan

Exercise price $7.02 per share Closing price on grant effective date May 4, 2026

Number of employees 2 employees Recipients of inducement stock option grants

Option term 10-year term Duration of granted stock options

Vesting period 4 years Total vesting timeline for the options

First-year vesting 25% of shares Cliff vesting on first anniversary of employment

Quarterly vesting rate 6.25% per quarter Equal installments over 12 quarters after first anniversary

Historical Context

5 past events · Latest: Apr 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Earnings and pipeline	Positive	-1.5%	Q1 2026 results with positive pociredir data and long cash runway.
Apr 27	Board appointment	Positive	-1.5%	Added experienced biotech executive Josh Lehrer to the board.
Apr 20	Earnings call notice	Neutral	-4.2%	Scheduled Q1 2026 results release and investor conference call.
Mar 19	Strategic partnership	Positive	+1.7%	Three-year collaboration to improve ED access for sickle cell patients.
Mar 06	Inducement grants	Neutral	-2.8%	Stock options granted to a new employee under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been met with mild negative or mixed price reactions, even when updates appeared operationally positive.

Recent Company History

Over the last few months, Fulcrum reported Q1 2026 results with positive pociredir Phase 1b data and a cash runway into 2029, yet the stock fell about 1.5% post‑release. A board appointment and an earlier inducement grant in March also coincided with modest declines. In contrast, a March partnership with MedicAlert and SCDAA produced a small gain. Today’s additional inducement grants fit the pattern of routine corporate updates layered onto an already loss‑making but well‑funded clinical‑stage story.

Key Terms

non-statutory stock options, Nasdaq Listing Rule 5635(c)(4)

2 terms

non-statutory stock options financial

"the company granted non-statutory stock options to two new employees"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees 55,500 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, May 4, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact: 

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

How many options did Fulcrum Therapeutics (FULC) grant on May 4, 2026?

Fulcrum granted a total of 55,500 stock options to two new employees. According to the company, the options were issued as inducement awards under its 2022 Inducement Stock Incentive Plan and tied to new hires entering employment.

What is the exercise price and term for the FULC inducement options?

The options have an exercise price of $7.02 per share and a 10-year term. According to the company, the $7.02 price equals the closing share price on the grant effective date, May 4, 2026.

What is the vesting schedule for the Fulcrum (FULC) inducement grants?

The options vest over four years: 25% on the first anniversary, then 6.25% each quarter for the next 12 quarters. According to the company, vesting is subject to the employees' continued service through each vesting date.

Why did Fulcrum use inducement grants under Nasdaq Rule 5635(c)(4) for FULC hires?

Inducement grants under Nasdaq Rule 5635(c)(4) allow equity awards to recruit key hires outside existing equity plans. According to the company, these options were material inducements for two new employees to enter employment with Fulcrum.

Will the 55,500 FULC options materially dilute existing shareholders?

The press release does not quantify total outstanding shares, so material dilution cannot be determined from the announcement alone. According to the company, 55,500 options were granted; investors must compare that to share count to assess dilution.